Study guide
Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance
EBP-EAP Examination in Paediatrics Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding
EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)
2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity
Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol
3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections
Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening
4 Chapter 4: Acute Paediatric Emergencies & Critical Care
EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination
5 Chapter 5: Paediatric Respiratory Medicine
Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations
6 Chapter 6: Paediatric Cardiology
Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever
7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition
Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure
8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance
Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management
9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism
Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)
10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health
Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy
11 Chapter 11: Paediatric Haematology & Oncology
Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia
12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy
Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules
13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions
The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia
14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics
Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics
15 Chapter 15: Paediatric Ophthalmology & ENT Disorders
Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions
16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health
Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance
17 Chapter 17: Adolescent Medicine & Healthcare Transition
Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition
18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics
Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics
19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine
Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy
Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance
Key Takeaways Explain This Topic AI
Paediatric DKA combines glucose >11 mmol/L, venous pH <7.30 or bicarbonate <18 mmol/L, and beta-hydroxybutyrate ≥3 mmol/L or moderate/large ketonuria. Grade acidosis using pH or bicarbonate: moderate <7.20 or <10 mmol/L; severe <7.10 or <5 mmol/L.
ISPAD 2022 recommends 10–20 mL/kg of 0.9% saline over 20–30 minutes for volume depletion without shock, and rapid 20 mL/kg aliquots with reassessment in shock. Replace the remaining 5–10% deficit plus maintenance over 24–48 hours, adjusting to clinical and biochemical response.
Start continuous IV soluble insulin at 0.05–0.1 units/kg/hour at least 1 hour after starting fluid replacement, after assessing potassium. Do not give an IV insulin bolus: it is unnecessary and can worsen hypokalaemia or precipitate circulatory compromise.
When blood glucose falls below 14 to 17 mmol/L (250-300 mg/dL), dextrose (5% then 10%) must be added to the intravenous fluids while maintaining the continuous insulin infusion to clear ketoacidosis and suppress lipolysis while avoiding hypoglycemia.
Cerebral oedema occurs in 0.5% to 1% of paediatric DKA presentations and represents the primary cause of mortality; acute clinical neurological deterioration mandates immediate bedside administration of 3% hypertonic saline (2.7-5 mL/kg over 10-15 minutes) or 20% mannitol (0.5-1 g/kg over 15-20 minutes) without delaying for neuroimaging.
Last updated: November 2026
Paediatric DKA Protocol and Type 1 Diabetes Mellitus Maintenance
Diabetic Ketoacidosis (DKA) is an acute, life-threatening emergency representing the initial manifestation in 25% to 40% of children newly diagnosed with Type 1 Diabetes Mellitus (T1DM) across Europe, and a recurrent hazard during intercurrent illnesses or insulin omission in established patients. Managing paediatric DKA requires understanding the physiological differences between children and adults: paediatric patients are uniquely susceptible to cerebral oedema , the leading cause of DKA-related mortality in childhood. Consequently, clinical guidelines from the International Society for Pediatric and Adolescent Diabetes (ISPAD 2022) and the European Society for Paediatric Endocrinology (ESPE) mandate a structured, cautious rehydration and insulin titration protocol.
Pathophysiology of Type 1 Diabetes Mellitus and DKA
Type 1 Diabetes Mellitus is an organ-specific autoimmune disorder characterized by the progressive, immune-mediated destruction of insulin-secreting pancreatic beta cells within the islets of Langerhans.
Genetic Susceptibility and Immunological Markers
Genetic Architecture: Strongest susceptibility maps to the major histocompatibility complex (MHC) class II region on chromosome 6p21, specifically alleles HLA-DR3-DQ2 and HLA-DR4-DQ8 . Over 90% of European children with T1DM carry at least one of these high-risk heterodimers.
Islet Autoantibodies: These markers help confirm the autoimmune classification of diabetes:
Anti-Glutamic Acid Decarboxylase (anti-GAD65): Most prevalent antibody, frequently persisting for years after diagnosis.
Anti-Islet Antigen 2 (anti-IA2): Directed against protein tyrosine phosphatase-like protein; correlates with rapid progression.
Anti-Zinc Transporter 8 (anti-ZnT8): Highly specific marker targeting the secretory granule zinc transporter.
Islet Cell Cytoplasmic Antibodies (ICA): Detected via indirect immunofluorescence against pancreatic sections. [Autoimmune Beta-Cell Destruction]
- |
- [Absolute Insulin Deficiency]
- |
- +----------------------------------------+----------------------------------------+
- | |
- [Counter-Regulatory Surge] [Impaired Glucose Uptake]
- (Glucagon, Adrenaline, Cortisol, GH) |
- | [Severe Hyperglycemia]
- +----------------------------------------+ |
- | [Glucosuria & Osmotic Diuresis]
- [Unrestrained Lipolysis] |
- | [Profound Dehydration &]
- [Massive Free Fatty Acid Flux] [Electrolyte Depletion]
- |
- [Hepatic Ketogenesis]
- (Acetoacetate & Beta-Hydroxybutyrate)
- |
- [Metabolic Ketoacidosis]
- The Ketoacidotic Metabolic Cascade
When functional beta-cell mass drops below 10% to 20% , absolute insulin deficiency combines with a massive compensatory surge of counter-regulatory stress hormones ( glucagon, adrenaline, cortisol, and growth hormone ):
Hyperglycemia: Unopposed glucagon drives hepatic glycogenolysis and accelerated gluconeogenesis using amino acids and glycerol substrates. Concurrently, peripheral glucose utilization by skeletal muscle and adipose tissue is markedly reduced, driving blood glucose well above the renal threshold (~10 mmol/L or 180 mg/dL).
Osmotic Diuresis and Dehydration: Glucosuria causes profound osmotic diuresis, with extensive urinary wasting of free water, sodium, potassium, chloride, magnesium, and phosphate. This produces hypovolemia, hyperosmolality, and reduced glomerular filtration.
Accelerated Lipolysis and Ketogenesis: Insulin deficiency disinhibits hormone-sensitive lipase in adipose tissue, releasing vast quantities of free fatty acids (FFAs) into the portal circulation. In hepatocytes, carnitine palmitoyltransferase-1 (CPT-1) channels FFAs into mitochondrial beta-oxidation, generating excess acetyl-CoA that is converted into ketone bodies: acetoacetate and beta-hydroxybutyrate .
High Anion Gap Metabolic Acidosis: Dissociation of ketone acids generates hydrogen ions that consume extracellular bicarbonate ( H C O 3 − HCO_3^- H C O 3 − ), producing severe metabolic acidosis with an elevated serum anion gap: Anion Gap = [ Na + ] − ( [ Cl − ] + [ HCO 3 − ] ) > 16 mmol/L \text{Anion Gap} = [\text{Na}^+] - ([\text{Cl}^-] + [\text{HCO}_3^-]) > 16\text{ mmol/L} Anion Gap = [ Na + ] − ([ Cl − ] + [ HCO 3 − ]) > 16 mmol/L
Diagnostic Criteria and Clinical Severity Grading
Biochemical confirmation of paediatric DKA requires fulfillment of the classic diagnostic triad :
Hyperglycemia: Blood glucose > 11.0 mmol/L > 11.0\text{ mmol/L} > 11.0 mmol/L (~ 200 mg/dL 200\text{ mg/dL} 200 mg/dL )
Metabolic Acidosis: Venous blood gas pH < 7.30 \text{pH} < 7.30 pH < 7.30 OR serum bicarbonate < 18.0 mmol/L < 18.0\text{ mmol/L} < 18.0 mmol/L
Ketoacidosis: Blood beta-hydroxybutyrate ≥ 3.0 mmol/L \ge 3.0\text{ mmol/L} ≥ 3.0 mmol/L OR moderate-to-large urine ketonuria ( ≥ 2 + \ge 2+ ≥ 2 + )
Note
Point-of-care capillary beta-hydroxybutyrate measurement is vastly superior to urine acetoacetate dipsticks. Beta-hydroxybutyrate is the predominant circulating ketone in acute DKA (ratio often 5:1 to 10:1 over acetoacetate) and reflects real-time metabolic response to therapy, whereas urine tests remain positive for days after ketoacidosis has fully resolved.
Severity Classification
Grade severity by venous pH or serum bicarbonate on presentation; use the more severe category if the results differ:
Severity Stage Venous Blood pH Serum Bicarbonate ( H C O 3 − HCO_3^- H C O 3 − ) Typical Clinical Presentation
Mild DKA 7.20 7.20 7.20 to < 7.30 < 7.30 < 7.30 10 10 10 to < 18 mmol/L < 18\text{ mmol/L} < 18 mmol/L Mild dehydration (~5%), compensated tachypnea, alert, nausea
Moderate DKA 7.10 7.10 7.10 to < 7.20 < 7.20 < 7.20 5 5 5 to < 10 mmol/L < 10\text{ mmol/L} < 10 mmol/L Moderate dehydration (5–7%), Kussmaul breathing, vomiting, abdominal pain
Severe DKA < 7.10 < 7.10 < 7.10 < 5 mmol/L < 5\text{ mmol/L} < 5 mmol/L Severe dehydration (7–10%), profound Kussmaul respiration, lethargy, weak pulses
ISPAD / European Fluid Resuscitation Protocol
Restore circulation first, then replace the estimated deficit with maintenance over 24–48 hours . In the PECARN trial, tested faster/slower and 0.45%/0.9% saline regimens did not differ in cerebral-injury risk. Follow an established protocol, reassess frequently and avoid unnecessary fluid restriction.
Step 1: Initial Volume Expansion
In volume-depleted children without shock, give 10–20 mL/kg of 0.9% saline over 20–30 minutes ; use 20 mL/kg when tissue perfusion is poor.
In shock, restore circulation rapidly with 20 mL/kg of 0.9% saline aliquots , reassessing after each and repeating when necessary.
Account for fluids already given before calculating the remaining deficit and ongoing replacement.
Step 2: Calculating Deficit and Maintenance Fluids
After initial volume expansion, choose a 24–48-hour replacement schedule. The following calculation illustrates a 48-hour schedule: Total Fluid over 48 Hours = Remaining Fluid Deficit + 48-Hour Maintenance Requirement \text{Total Fluid over 48 Hours} = \text{Remaining Fluid Deficit} + \text{48-Hour Maintenance Requirement} Total Fluid over 48 Hours = Remaining Fluid Deficit + 48-Hour Maintenance Requirement
Estimate Fluid Deficit:
Mild DKA: Assume 5% ( 50 mL/kg 50\text{ mL/kg} 50 mL/kg ); moderate DKA: 7% ( 70 mL/kg 70\text{ mL/kg} 70 mL/kg ).
Severe DKA: Assume 10% ( 100 mL/kg 100\text{ mL/kg} 100 mL/kg ).
Subtract the initial expansion volume already given from the estimated deficit to determine the remaining deficit .
Calculate Maintenance Fluid:
Use the standard Holliday-Segar method :
First 10 kg 10\text{ kg} 10 kg : 100 mL/kg/day 100\text{ mL/kg/day} 100 mL/kg/day
Next 10 kg 10\text{ kg} 10 kg ( 11 – 20 kg 11\text{--}20\text{ kg} 11 – 20 kg ): Add 50 mL/kg/day 50\text{ mL/kg/day} 50 mL/kg/day
Each kg > 20 kg \text{kg} > 20\text{ kg} kg > 20 kg : Add 20 mL/kg/day 20\text{ mL/kg/day} 20 mL/kg/day (maximum 2 , 000 – 2 , 500 mL/day 2,000\text{--}2,500\text{ mL/day} 2 , 000 – 2 , 500 mL/day )
Multiply the daily maintenance by 2 to yield the 48-hour requirement.
Hourly Infusion Rate:
Evenly divide the sum of remaining deficit and 48-hour maintenance across 48 hours : Hourly Fluid Rate (mL/h) = Remaining Deficit (mL) + 48-h Maintenance (mL) 48 hours \text{Hourly Fluid Rate (mL/h)} = \frac{\text{Remaining Deficit (mL)} + \text{48-h Maintenance (mL)}}{48\text{ hours}} Hourly Fluid Rate (mL/h) = 48 hours Remaining Deficit (mL) + 48-h Maintenance (mL)
Warning
Reassess perfusion, fluid balance, neurological status and electrolytes throughout treatment. Adjust the prescribed deficit-plus-maintenance rate to the response; do not impose an arbitrary maintenance-multiple cap that leaves circulation inadequately supported.
- Insulin Therapy: The Strict 1-Hour Delay Rule [Hour 0: Begin Initial Fluid Volume Expansion]
- |
- [DO NOT GIVE INSULIN]
- |
- [Hour >=1: Reassess Perfusion and Potassium]
- |
- +-------------------+-------------------+
- | |
- [Serum K+ >= 3.5 mmol/L] [Serum K+ < 3.5 mmol/L]
- | |
- [START CONTINUOUS INSULIN] [HOLD INSULIN INFUSION]
- Soluble regular insulin - Add 40 mmol/L KCl to IV fluids
- Dose: 0.05 to 0.1 units/kg/h - Wait until K+ >= 3.5 mmol/L
- NO INTRAVENOUS BOLUS! - Then start insulin infusion
- The Mandatory 1-Hour Delay
Insulin therapy must STRICTLY BE DELAYED until at least 1 hour AFTER intravenous fluid rehydration has commenced. Rationale:
Intravenous fluid expansion alone restores renal perfusion, increases urinary glucose excretion, and blunts counter-regulatory hormones, smoothly dropping blood glucose by 3 to 5 mmol/L/hour before insulin is introduced.
Insulin given before circulation is supported can reduce intravascular volume through falling glucose and osmotic pressure, worsen hypokalaemia and precipitate circulatory compromise.
Start insulin after initial volume expansion. Earlier insulin has been associated with cerebral injury, and insulin can worsen hypokalaemia or compromise perfusion if given before circulation is supported.
Insulin Dosing and Delivery
Continuous Intravenous Infusion: Unbuffered soluble (regular) insulin at 0.05 to 0.1 units/kg/hour (e.g., 50 units Actrapid in 50 mL 0.9% saline, running at 0.05 – 0.1 mL/kg/hour 0.05\text{--}0.1\text{ mL/kg/hour} 0.05 – 0.1 mL/kg/hour ).
In young children (<5 years) or mild/moderate DKA, a lower dose of 0.05 units/kg/hour is preferred to achieve a controlled glycemic decline.
NO INITIAL INTRAVENOUS INSULIN BOLUS: It is unnecessary, can precipitate circulatory compromise through a rapid fall in osmotic pressure, and can exacerbate hypokalaemia.
Glucose Maintenance and Addition of Dextrose
The therapeutic goal of insulin is to halt lipolysis and reverse ketoacidosis , not simply normalize blood glucose.
Target rate of glucose decline: 3 to 5 mmol/L/hour (avoid dropping faster than 5 mmol/L/hour 5\text{ mmol/L/hour} 5 mmol/L/hour or 90 mg/dL/hour 90\text{ mg/dL/hour} 90 mg/dL/hour ).
When blood glucose drops below 14 to 17 mmol/L (250 to 300 mg/dL):
Continue insulin to suppress ketogenesis. Add dextrose; reduce insulin if hypoglycaemia or hypokalaemia persists despite appropriate treatment, while following ketone clearance.
Immediately add 5% Dextrose (and subsequently 10% Dextrose if necessary) to the IV fluids.
The "two-bag system" (one bag of 0.9 % NaCl + KCl 0.9\%\text{ NaCl} + \text{KCl} 0.9% NaCl + KCl , second bag of 10 % Dextrose + 0.9 % NaCl + KCl 10\%\text{ Dextrose} + 0.9\%\text{ NaCl} + \text{KCl} 10% Dextrose + 0.9% NaCl + KCl ) allows rapid bedside titration of glucose delivery while keeping total fluid and insulin infusion rates constant.
Maintain blood glucose between 8 and 12 mmol/L (150 to 220 mg/dL) until ketoacidosis resolves.
Potassium and Electrolyte Management
Children with DKA suffer from profound total body potassium depletion (typically 3 to 6 mmol/kg deficit) caused by urinary potassium wasting during osmotic diuresis and gastrointestinal losses from vomiting.
The Paradoxical Serum Potassium
Despite massive total body deficits, initial serum potassium levels are frequently normal or elevated (e.g., 5.0 to 6.5 mmol/L). This occurs because:
Extracellular hyperosmolality pulls water and potassium out of cells.
Intracellular acidosis causes exchange of intracellular potassium for extracellular hydrogen ions.
Absence of insulin prevents normal Na+/K+-ATPase-mediated cellular potassium uptake.
Replacement Protocol
If serum potassium is normal or elevated (<5.5 mmol/L): Add 40 mmol/L Potassium Chloride (KCl) (or a 50:50 mixture of potassium chloride and potassium phosphate) to the IV fluids as soon as urine output is established or after initial rehydration.
If serum potassium is < 3.5 mmol/L < 3.5\text{ mmol/L} < 3.5 mmol/L at baseline: Add 40 mmol/L KCl immediately and HOLD insulin therapy until potassium rises above 3.5 mmol/L 3.5\text{ mmol/L} 3.5 mmol/L . Administering insulin during severe hypokalemia drives remaining potassium into cells, triggering fatal cardiac arrhythmias (ventricular fibrillation, asystole).
If serum potassium is > 5.5 mmol/L > 5.5\text{ mmol/L} > 5.5 mmol/L : Defer potassium in IV fluids; monitor hourly and start 40 mmol/L KCl as soon as potassium falls below 5.5 mmol/L 5.5\text{ mmol/L} 5.5 mmol/L .
Warning
Sodium Bicarbonate: Avoid Routine Use Fluid and insulin treatment reverse ketoacidosis; controlled trials show no clinical benefit from routine bicarbonate. Bicarbonate may cause paradoxical CNS acidosis and hypokalaemia, and its use has been associated with cerebral injury.
Reserve it for life-threatening hyperkalaemia or unusually severe acidosis (venous pH <6.9) with compromised cardiac contractility , with specialist supervision.
Cerebral Oedema: Recognition and Bedside Emergency Management
Cerebral oedema develops in 0.5% to 1% of paediatric DKA episodes and accounts for 60% to 90% of all DKA-related deaths. The condition typically manifests between 4 and 12 hours into treatment, during the period of maximal biochemical and osmolar shift.
- High-Risk Predictors for Cerebral Oedema
- Younger age (<5 years) and newly diagnosed Type 1 diabetes
Greater severity of presentation: lower venous pH ( < 7.10 <7.10 < 7.10 ), higher baseline serum urea / BUN, lower bicarbonate
Administration of an initial intravenous insulin bolus
Bicarbonate administration has been associated with cerebral injury.
Corrected sodium helps interpret water balance: [ Corrected Na + ] = [ Measured Na + ] + 1.6 × [ ( Glucose − 5.5 ) / 5.5 ] [\text{Corrected Na}^+] = [\text{Measured Na}^+] + 1.6 \times [(\text{Glucose} - 5.5) / 5.5] [ Corrected Na + ] = [ Measured Na + ] + 1.6 × [( Glucose − 5.5 ) /5.5 ] . Follow sodium trends with the clinical response; ISPAD 2022 does not require sodium to rise routinely as glucose falls.
Diagnostic Warning Signs
Diagnostic Category Clinical Features
Major Criteria Depressed or fluctuating level of consciousness (Glasgow Coma Scale score drop ≥ 2 \ge 2 ≥ 2 points); Sustained bradycardia (drop > 20 bpm >20\text{ bpm} > 20 bpm not related to sleep); Incontinence inappropriate for age
Minor Criteria Persistent or worsening headache; Vomiting after initial improvement; Lethargy or difficulty being aroused; Diastolic blood pressure > 90 mmHg >90\text{ mmHg} > 90 mmHg ; Age < 5 <5 < 5 years
Late Signs of Herniation Decerebrate or decorticate posturing; Asymmetrical, dilated, or sluggish pupils; Papilledema; Cheyne-Stokes breathing; Respiratory arrest
Immediate Emergency Pharmacotherapy
Caution
DO NOT DELAY FOR A HEAD CT SCAN! If cerebral oedema is suspected clinically, immediately administer hyperosmolar therapy at the bedside before any transport. Brain herniation can occur within minutes. Neuroimaging is performed only after pharmacological stabilization.
Hyperosmolar Therapy (Choose either agent immediately):
Hypertonic 3% Saline: 2.7 to 5.0 mL/kg administered IV over 10 to 15 minutes . (Preferred in many European tertiary centres; maintains systemic intravascular volume while drawing water from brain parenchyma).
20% Mannitol: 0.5 to 1.0 g/kg ( 2.5 to 5.0 mL/kg 2.5\text{ to }5.0\text{ mL/kg} 2.5 to 5.0 mL/kg ) administered IV over 15 to 20 minutes .
Repeat the dose in 30 minutes if there is no clinical improvement.
Supportive Bedside Actions:
Elevate the head of the bed to 30 degrees in the midline.
Adjust IV fluids to maintain normal blood pressure while avoiding excessive administration. Avoid hypotension, which compromises cerebral perfusion; seek immediate intensive-care support.
Support airway and oxygenation; obtain expert help if intubation is needed. Match ventilation to the compensation expected for the metabolic acidosis and avoid excessive hypocapnia; abrupt loss of compensation also worsens acidosis.
Outpatient T1DM Maintenance and Technology
After clinical improvement and resolution of ketosis (beta-hydroxybutyrate < 1.0 mmol/L <1.0\text{ mmol/L} < 1.0 mmol/L or a closed anion gap), transition to subcutaneous insulin. Residual hyperchloraemic acidosis need not delay transition. Give rapid-acting subcutaneous insulin 15–30 minutes before stopping IV insulin; basal insulin requires a longer overlap.
Subcutaneous Regimens
Multiple Daily Injections (MDI): Basal-bolus regimen consisting of once- or twice-daily long-acting analogue (Insulin Glargine, Degludec, or Detemir) providing 40% to 50% of total daily dose, plus rapid-acting analogue (Insulin Aspart, Lispro, or Glulisine) before meals calculated based on carbohydrate ratios and insulin sensitivity factors.
Continuous Subcutaneous Insulin Infusion (CSII / Insulin Pumps): Continuous basal infusion of rapid-acting insulin with programmed boluses. Modern Hybrid Closed-Loop (AID) Systems integrate continuous glucose monitors (CGM) with predictive algorithms that automatically modulate basal insulin delivery and administer micro-boluses, achieving superior glycemic control.
Glycemic Targets (ISPAD Guidelines)
Target HbA1c (ISPAD 2024): ≤ 6.5 % \le6.5\% ≤ 6.5% (48 mmol/mol) with advanced technology and support when safely achievable; otherwise ≤ 7.0 % \le7.0\% ≤ 7.0% (53 mmol/mol). Individualize to hypoglycaemia risk and treatment burden.
Continuous Glucose Monitoring (CGM) Metrics:
- Time in Range (TIR, 3.9–10.0 mmol/L / 70–180 mg/dL): > 70 % > 70\% > 70%
- Time Below Range (TBR, <3.9 mmol/L / <70 mg/dL): < 4 % < 4\% < 4%
- Time in Clinically Important Hypoglycaemia (<3.0 mmol/L / <54 mg/dL): < 1 % < 1\% < 1%
- Acute Hypoglycemia Protocol
Hypoglycaemia in a conscious child able to swallow:
Give approximately 0.3 g/kg of fast-acting glucose (e.g., 9 g for 30 kg; about 15 g for ≥50 kg). A smaller amount may suffice with automated insulin delivery.
Recheck glucose after 15 minutes ; repeat treatment if still low.
Give additional carbohydrate if needed to prevent recurrence when a meal is not imminent.
Severe Hypoglycemia (unconscious, convulsing):
Outpatient Emergency: Intramuscular (IM) Glucagon :
- Body weight < 25 kg <25\text{ kg} < 25 kg : 0.5 mg IM
- Body weight ≥ 25 kg \ge25\text{ kg} ≥ 25 kg : 1.0 mg IM
Alternative: Intranasal Glucagon powder (Baqsimi) : 3 mg into one nostril , authorized in the EU for age ≥ 1 year \ge1\text{ year} ≥ 1 year .
In-Hospital Emergency: Intravenous 10% Dextrose bolus of 2.0 to 5.0 mL/kg infused over 5 to 10 minutes, followed by maintenance 10% dextrose.